Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Arie Belldegrun
AddedMar 31, 2024
UpdatedJun 28, 2026
Arie Belldegrun

Arie Belldegrun

Founder, Kite Pharma

CrunchbaseLinkedIn

Arie Belldegrun's Career

Kite Pharma
Kite Pharma

Santa Monica, CA, US

Founder
Pontifax
Pontifax

Herzliya, Tel Aviv District, IL

Board Member· Board
Bellco Capital
Bellco Capital

Los Angeles, CA, US

Board Member· Board
Two River
Two River

New York City, NY, US

Board Member· Board
UroGen Pharma
UroGen Pharma

New York City, NY, US

Board Member· Board
Kronos Bio
Kronos Bio

San Mateo, CA, US

Board Member· Board
Allogene Therapeutics
Allogene Therapeutics

South San Francisco, CA, US

Board Member· Board
Ginkgo Bioworks
Ginkgo Bioworks

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Arie Belldegrun's Career

Kite Pharma
Kite Pharma

Santa Monica, CA, US

Founder
Pontifax
Pontifax
Investment FirmInvestment Firm422004Herzliya, Tel Aviv District, IL
Board Member· Board

Leadership at Pontifax

Ran NussbaumRan NussbaumCo-Founder
Tomer KarivTomer KarivCo-Founder & CEO
Bellco Capital
Bellco Capital
Investment FirmInvestment Firm312004Los Angeles, CA, US
Board Member· Board

Leadership at Bellco Capital

Rebecka BelldegrunRebecka BelldegrunCEO

Similar to Bellco Capital

Belle CapitalBelle CapitalDouglas, AZ, USest. 2013Belle CapitalDouglas, AZ, US · est. 2013

Belle Capital LP: A US-based venture capital firm investing in mobile, internet, IT, life sciences, and clean tech sectors.

Investment Firm175
Marc Bell CapitalMarc Bell CapitalBoca Raton, FL, USest. 2003Marc Bell CapitalBoca Raton, FL, US · est. 2003

Marc Bell Capital: A Florida-based private equity firm specializing in diverse investments, primarily in commercial and real estate sectors.

Investment Firm30
Corbel Capital PartnersCorbel Capital PartnersLos Angeles, CA, USest. 2013Corbel Capital PartnersLos Angeles, CA, US · est. 2013

LA-based Corbel Capital Partners is a private equity firm specializing in non-control consumer and retail investments.

Investment Firm24
Colbeck Capital ManagementColbeck Capital ManagementNew York City, NY, USest. 2009Colbeck Capital ManagementNew York City, NY, US · est. 2009

Colbeck Capital Management, LLP: A private credit manager specializing in distressed debt and strategic lending.

Investment Firm22
Two River
Two River
Investment FirmInvestment Firm162004New York City, NY, US
Board Member· Board

Leadership at Two River

David TanenDavid TanenCo-Founder
Joshua KazamJoshua KazamCo-Founder
UroGen Pharma
UroGen Pharma

New York City, NY, US

Board Member· Board
Kronos Bio
Kronos Bio
Public$278M1052017San Mateo, CA, US
Board Member· Board

Leadership at Kronos Bio

Norbert BischofbergerNorbert BischofbergerBoard Member
Elena RidloffElena RidloffBoard Member
Otello StampacchiaOtello StampacchiaBoard Member
Angela KoehlerAngela KoehlerCo-Founder
Marianne De BackerMarianne De BackerBoard Member

Similar to Kronos Bio

Clovis OncologyClovis OncologyBoulder, CO, USCancer Treatmentsest. 2009Clovis OncologyBoulder, CO, US · est. 2009

Clovis Oncology, a global biotech firm, specializes in developing and commercializing cancer treatments.

Public · $145M413
BeOne MedicinesBeOne MedicinesCambridge, MA, USCancer Treatmentsest. 2010BeOne MedicinesCambridge, MA, US · est. 2010

BeiGene, a global biopharmaceutical firm, specializes in developing targeted and immuno-oncology cancer treatments.

Public · $6.8B10k
Revolution MedicinesRevolution MedicinesRedwood City, CA, USOncology Therapiesest. 2014Revolution MedicinesRedwood City, CA, US · est. 2014

US-based Revolution Medicines, Inc. discovers novel oncology therapies targeting elusive growth pathways globally.

Public · $1.1B246
Allogene Therapeutics
Allogene Therapeutics
Public$781.8M3612017South San Francisco, CA, US
Board Member· Board

Leadership at Allogene Therapeutics

David ChangDavid ChangFounder
Liz BarrettLiz BarrettBoard Member
Stephen L. MayoStephen L. MayoBoard Member
Debbie MessemerDebbie MessemerBoard Member
Owen WitteOwen WitteBoard Member
John DeYoungJohn DeYoungBoard Member
Ginkgo Bioworks
Ginkgo Bioworks
Public$1.6B1.3k2009Boston, MA, US
Board Member· Board

Leadership at Ginkgo Bioworks

Shyam SankarShyam SankarBoard Member
Harry Evans SloanHarry Evans SloanBoard Member
Reshma ShettyReshma ShettyFounder
Tom KnightTom KnightFounder
Marijn DekkersMarijn DekkersBoard Member
Jason KellyJason KellyFounder

Arie Belldegrun's Co-Investors

John C. MartinJohn C. MartinCo-invested · Kronos Bio Seed

Arie Belldegrun's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Arie Belldegrun

Mitchell BluttMitchell BluttBoard Member · Consonance CapitalLyle BerkowitzLyle BerkowitzCo-Founder · 2Flo VenturesLouis AronneLouis AronneCo-Founder · IntellihealthDavid AgusDavid AgusBoard Member · Thrive GlobalJames MinJames MinFounder · CleerlyCharles SchleienCharles SchleienBoard Member · Northwell Health